Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9480	Companies
185564	Keywords
117971	Articles
99400	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 12/19/2024 at 15:00, 11 months 17 days ago

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Magdalena explores coca leaf's therapeutic benefits for ADHD and neuropsychiatric indications in partnership with Peru. Jaguar's Dr. King to present at Wisdom of the Leaf Coca Summit on coca-based Botanical Drugs

ADHD Peru Botanical Drugs Magdalena Coca Leaf
BRIEF

published on 12/18/2024 at 16:05, 11 months 18 days ago

Jaguar Health lance une étude de phase 2 sur la maladie d'inclusion des microvillosités

Crofelemer Désignation De Médicament Orphelin Étude De Phase 2 Santé Jaguar MVID
BRIEF

published on 12/18/2024 at 16:05, 11 months 18 days ago

Jaguar Health Launches Phase 2 Study for Microvillus Inclusion Disease

Crofelemer Jaguar Health Orphan-Drug Designation Phase 2 Study MVID
PRESS RELEASE

published on 12/18/2024 at 16:00, 11 months 18 days ago

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
Jaguar Health, Inc. initiates Phase 2 study for crofelemer, a novel plant-based drug, in pediatric MVID patients. Study aims to evaluate drug efficacy for rare diseases MVID and SBS-IF

Crofelemer Jaguar Health Inc. Phase 2 Study Pediatric Patients MVID
BRIEF

published on 12/17/2024 at 14:35, 11 months 19 days ago

La FDA accorde la désignation de médicament orphelin au Crofelemer de Jaguar Health pour le traitement du choléra

Crofelemer Désignation De Médicament Orphelin Approbation De La FDA Santé Jaguar Traitement Du Choléra
BRIEF

published on 12/17/2024 at 14:35, 11 months 19 days ago

FDA Grants Orphan-Drug Designation to Jaguar Health's Crofelemer for Cholera

Crofelemer FDA Approval Jaguar Health Orphan-Drug Designation Cholera Treatment
PRESS RELEASE

published on 12/17/2024 at 14:30, 11 months 19 days ago

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
World Health Organization (WHO) elevates cholera to highest emergency level due to global resurgence. Crofelemer granted orphan-drug designation by FDA and EMA for cholera treatment

FDA Crofelemer Cholera Orphan-Drug Designation World Health Organization
BRIEF

published on 12/13/2024 at 16:05, 11 months 23 days ago

Ladenburg Thalmann organise une exposition scientifique sur le Crofelemer de Jaguar Health

Crofelemer Maladies Rares Santé Jaguar Napo Thérapeutique Vitrine Scientifique
BRIEF

published on 12/13/2024 at 16:05, 11 months 23 days ago

Ladenburg Thalmann to Host Scientific Showcase on Jaguar Health's Crofelemer

Crofelemer Jaguar Health Rare Diseases Napo Therapeutics Scientific Showcase
PRESS RELEASE

published on 12/13/2024 at 16:00, 11 months 23 days ago

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
Jaguar Health, Inc. announces virtual event on crofelemer clinical development efforts for rare diseases MVID and SBS-IF. CEO awarded 'Best CEO BioPharmaceuticals of the Year'

Crofelemer Clinical Development Jaguar Health Rare Diseases MVID

Accesswire

Published on 12/06/2025 at 02:00, 3 hours 57 minutes ago

Northern Dynasty Provides Update on Board Search and Audit & Risk Committee Composition
Published on 12/06/2025 at 01:15, 4 hours 42 minutes ago

Prospect Ridge Announces Closing of Flow-Through Unit Private Placement
Published on 12/06/2025 at 00:25, 5 hours 32 minutes ago

GMV Minerals Announces Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/06/2025 at 00:00, 5 hours 57 minutes ago

Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 6 hours 27 minutes ago

55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 7 hours 42 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 7 hours 45 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 10 hours 59 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 11 hours 31 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 11 hours 42 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 6 hours 57 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 6 hours 57 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 6 hours 57 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 6 hours 57 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 12 hours 39 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE